Analyse the territories with increasing gap to goal compared to previous quarters

Identify the territories that have performance less than/far from the national average

Analyse the competitor product performance compared to our Product

Re-Engage lapsed strategic accounts to reduce near term risk

Refocus efforts on high impact activites tied to SP & SD Sales

HIGH RELIVE new patient starts 9% below forecast nationally; $3.8M projected quarterly gap

HIGH Wisconsin and upper Midwest driving 54% of national new-patient-start gap

MED Milwaukee and rural Wisconsin metros showing 5+ weeks of new-patient-start decline vs. national baseline

MED Field call coverage on target neurologists dropped below 75% goal for 3 consecutive weeks in Wisconsin

HIGH Competitor X messaging on safety profile gaining traction with community neurologists; SOV up 18%

LOW No material payer changes flagged; access environment stable for RELIVE across commercial and Medicare

HIGH Community neurology group (Wisconsin): new patient starts down 40% over 6 weeks

HIGH ATU Q3 wave: neurologist concern about RELIVE GI side effects up 11 points vs. Q2

MED Patient-level data: fewer treatment-naive patients progressing to therapy initiation in affected geographies